Climb Bio Inc (CLYM) Wheel Strategy

Running a CLYM wheel strategy lets you generate consistent premium income on Climb Bio Inc while setting your own entry and exit prices on the underlying. Climb Bio Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own CLYM, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best CLYM wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on CLYM, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable CLYM wheel from a losing one.

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the CLYM wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your CLYM wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.